Lumiracoxib: less gastroduodenal toxicity than ibuprofen

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1010, 2004-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lumiracoxib [Prexige] appears to have a significantly less impact on BP than ibuprofen in patients with osteoarthritis who also have controlled hypertension

Reactions Weekly, Vol. 1, Iss. 1157, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Lumiracoxib

By Katherine A. Lyseng-Williamson Monique P. Curran

Drugs, Vol. 64, Iss. 19, 2004-01 ,pp. : 2237-2246

Adis International

Access to resources Recommend Favorite

CS 706 [R109339], a novel COX-2-selective inhibitor, is associated with less GI toxicity than naproxen

Inpharma, Vol. 1, Iss. 1584, 2007-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Pharma industry less than healthy

Inpharma, Vol. 1, Iss. 1627, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Less liver toxicity with localised chemotherapy

Inpharma, Vol. 1, Iss. 1615, 2007-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite